Neil Kumar Healthcare News

This is selected healthcare news for Neil Kumar, which is filed under People. There are 127 news items for this page.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source
6/9/2022 #BIO22 Live Panel and Meet & Greet: Biopharma at the Crossroads – June 14th
... sciences and health economics and outcomes research ( HEOR ) professionals. Joining him are a list of executives from several high profile biotech organizations, including Andrew Lo from MIT, Kristina Burow, managing director of ARCH, Neil Kumar, CEO of BridgeBio, Gossamer CEO Faheem Hasnain and Paul Hastings, the CEO of Nkarta. According ...
healtheconomics.com
4/25/2022 How a surprise finding made an Alnylam study one of biotech's most 'polarizing' trials
... walking test closely correlated with heart health. Those individuals were expected to do much worse over one year of study. Instead, they barely declined. ‚AuThat was a head scratcher,‚Au said BridgeBio CEO Neil Kumar, in an interview. ‚AuThere was no evidence,‚Au based on several past trials, to suggest ...
BioPharma Dive
12/28/2021 BridgeBio Announces ATTRibute-CM Month 12 Primary Endpoint Miss; Shares Plunge 72% | Nasdaq
... show positive Month 30 endpoint results, which include all-cause mortality and cardiovascular hospitalizations. An independent data monitoring committee also recommends continuing the study based on unblinded data reviews. Official Comments BridgeBio CEO Neil Kumar said, ‚AuThis result is disappointing and baffling. I am, along with many others, searching for ...
Nasdaq
12/27/2021 BridgeBio Plunges After Acoramidis Study Fails to Meet Primary Endpoint Yahoo News
12/27/2021 BridgeBio Plunges After Acoramidis Study Fails to Meet Primary Endpoint MSN
12/27/2021 BridgeBio Pharma: ATTRibute-CM Study Fails To Meet Primary Endpoint At Month 12 | Nasdaq Nasdaq
12/27/2021 BridgeBio Stock Sinks After Acoramidis Phase 3 Trial Fails to Meet Endpoint MarketWatch
12/27/2021 BridgeBio Pharma Stock Sinks After Trial Fails to Meet Endpoint - MarketWatch MarketWatch
8/5/2021 BridgeBio Pharma, Inc. Reports Second Quarter 2021 Financial Results and Business Update PR Newswire
12/21/2020 Author Correction: Supporting US public health experts squidnews.net
10/21/2020 Salk Institute BridgeBio Pharma Collaborate to Advance Therapies for Genetically Driven Disease Nasdaq:BBIO Globe Newswire
10/21/2020 BridgeBio Pharma, Inc. and the University of Colorado Anschutz Medical Campus Collaborate to Advance Medicines for Genetically Driven Diseases Globe Newswire
10/21/2020 BridgeBio Pharma, Inc. and the University of Colorado Anschutz Medical Campus Collaborate to Advance Medicines for Genetically Driven Diseases Nasdaq:BBIO Globe Newswire
9/22/2020 BridgeBio Pharma to Host Virtual R&D Day on September 29, 2020 Globe Newswire
8/15/2020 Week in Review: $2.5 Billion in Deals including LianBio's Initial $719 Million in In-Licensings subhub.com
8/11/2020 BridgeBio Pharma, Inc. Reports Second Quarter 2020 Financial Results and Business Update Nasdaq:BBIO Globe Newswire
8/11/2020 LianBio Forms $531.5 Million China Partnership with BridgeBio for Two Oncology Candidates subhub.com
8/11/2020 BridgeBio Pharma Exps Reach Into China and Other Major Asian Markets Through Strategic Collaboration With Perceptive Advisors-Founded Company, LianBio BioSpace
8/11/2020 BridgeBio Pharma, Inc. Reports Second Quarter 2020 Financial Results Business Update BioSpace
8/11/2020 BridgeBio Pharma Expands Reach Into China and Other Major Asian Markets Through Strategic Collaboration With Perceptive Advisors-Founded Company, LianBio Globe Newswire
8/8/2020 Eidos Therapeutics Appoints Industry Leaders With Significant Development and Commercial Expertise to Board of Directors FirstWord PHARMA
8/7/2020 Eidos Therapeutics Appoints Industry Leaders With Significant Development and Commercial Expertise to Board of Directors Globe Newswire
8/7/2020 Eidos Therapeutics Appoints Industry Leaders With Significant Development and Commercial Expertise to Board of Directors Nasdaq:EIDX Globe Newswire
8/7/2020 Eidos Therapeutics Reports and Business Update BioSpace
8/7/2020 Eidos Therapeutics Appoints Industry Leaders With Significant Development and Commercial Expertise to Board of Directors Benzinga